Research Topics
| Benjamin M SciricaSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
Clin Chem 53:1800-7. 2007..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Am Heart J 162:818-825.e6. 2011....- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Lancet 380:1317-24. 2012..We tested this effect in a subgroup of patients from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial... - Acute coronary syndrome: emerging tools for diagnosis and risk assessmentBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 55:1403-15. 2010..This review identifies promising new or emerging techniques, as well as established tools, and reviews their current or potential role in clinical practice... - Ranolazine in patients with angina and coronary artery diseaseBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Curr Cardiol Rep 9:272-8. 2007..Ranolazine complements traditional antianginal agents and offers clinicians a new option in the long-term treatment of patients with angina... - Ranolazine in patients with coronary artery diseaseBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Expert Opin Pharmacother 8:2149-57. 2007..Thus, ranolazine offers clinicians a new therapy in the long-term treatment of patients with chronic angina... - Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less IschemBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
Circulation 116:1647-52. 2007..Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans... - Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular deathBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Clin Chem 55:265-73. 2009.... - The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogrBenjamin M Scirica
TIMI Study Group, Brigham and Women s Hospital, Cardiovascular Division, 350 Longwood Avenue, Boston, MA 02215, USA
J Am Coll Cardiol 57:1908-16. 2011.... - Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trialBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Eur Heart J 32:697-705. 2011.... - Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial InfarctiBenjamin M Scirica
TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 53:1411-21. 2009..The purpose of this study was to assess the relationship between ischemia detected on continuous electrocardiographic (cECG) recording and cardiovascular outcomes after acute coronary syndrome (ACS)... - Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrBenjamin M Scirica
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
Circulation 122:455-62. 2010..The incidence and prognostic implications of VT in patients with non-ST-elevation acute coronary syndrome receiving contemporary care have not been examined... - Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Eur Heart J 31:1993-2005. 2010.... - A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
Eur Heart J 28:2070-6. 2007..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis... - Treatment of elevated cholesterolBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 111:e360-3. 2005 - Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trialBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
J Thromb Thrombolysis 22:95-102. 2006..To assess etiology and impact of thrombocytopenia in a large oral glycoprotein (GP) IIb/IIIa inhibitor trial... - The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 StudyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 48:37-42. 2006..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis... - Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 47:2326-31. 2006..We aimed to determine whether intensive statin therapy reduces hospitalization for heart failure (HF) in high-risk patients... - Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromesMarc P Bonaca
Brigham and Women s Hospital, Boston, Massachusetts, USA
J Am Coll Cardiol 60:332-8. 2012..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)... - Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarctionJames R Harkness
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
Am Heart J 159:55-62. 2010..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score... - Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trialDavid A Morrow
TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Mass 02115, USA
JAMA 297:1775-83. 2007..Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)... - Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PRC Michael Gibson
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
Am Heart J 152:756-61. 2006..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)... - Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in MyocardiDavid A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 119:2758-64. 2009..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI... - Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
Am J Cardiol 99:344-8. 2007..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication... - Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)Jessica L Mega
Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
Circulation 121:1809-17. 2010..In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women... - Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatmentMarc S Sabatine
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
Circulation 111:1217-24. 2005..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear... - Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 TrialSean R Wilson
Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
J Am Coll Cardiol 53:1510-6. 2009..We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with angina than previously studied... 
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARMatthew W Sherwood
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am Heart J 159:964-971.e1. 2010..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...- Vorapaxar in the secondary prevention of atherothrombotic eventsDavid A Morrow
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
N Engl J Med 366:1404-13. 2012..Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1... - Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classificationBenjamin M Scirica
Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Am J Cardiol 90:821-6. 2002..Given their high risk for adverse events, patients with secondary UAP should be treated aggressively... - B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-ThrDavid A Morrow
Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 55:1189-96. 2010..We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial... - Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trialDavid A Morrow
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
Am Heart J 151:1186.e1-9. 2006..CONCLUSIONS: MERLIN-TIMI 36 will evaluate the role of ranolazine in the acute and chronic management of patients presenting with NSTE-ACS... - Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trialPayal Kohli
TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Clin Chem 58:257-66. 2012..We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial... - Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 triChristopher P Cannon
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 50:1844-51. 2007..Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)... - Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registryBenjamin M Scirica
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Am J Cardiol 90:303-5. 2002 - Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trialDavid A Morrow
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 119:2032-9. 2009..We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial... - Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees PDavid A Morrow
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 158:335-341.e3. 2009..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents... - Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomiStephen D Wiviott
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
Lancet 371:1353-63. 2008..We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study... - Troponins in acute coronary syndromesBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Prog Cardiovasc Dis 47:177-88. 2004..Future generations of troponin assays may detect specific posttranslational modifications of troponins that may increase the analytic sensitivity for myocardial damage and offer insight into the timing and mechanism of myocardial injury... - Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial)James R Harkness
TIMI Study Group, Boston, Massachusetts, USA
Am J Cardiol 108:1373-81. 2011.... - Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--GMitul B Kadakia
TIMI Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
JACC Cardiovasc Interv 3:1166-77. 2010..The aim of this study was to evaluate anticoagulant use patterns and bleeding risk in a contemporary population of patients with acute coronary syndrome... - Troponins in acute coronary syndromesBenjamin M Scirica
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Semin Vasc Med 3:363-74. 2003.... - Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitusJacob A Udell
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Clin Cardiol 35:722-9. 2012..In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus... - Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION RegistryRavi V Shah
Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Circ Heart Fail 5:693-702. 2012..Patients with acute myocardial infarction (MI) complicated by heart failure (HF) are subject to higher mortality during the index hospitalization. Early risk prediction and intervention may help prevent HF-related morbidity and mortality... - Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis)C Michael Gibson
TIMI Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Am J Cardiol 104:36-40. 2009..Holter monitoring may be a useful surrogate end point in clinical trials... - Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJessica L Mega
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 306:2221-8. 2011..Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel... - Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphologyZeeshan Syed
Harvard MIT Division of Health Sciences and Technology, Cambridge, MA, USA
Am J Cardiol 103:307-11. 2009..In conclusion, our results suggest that increased variation in the entire heart beat morphology is associated with a considerably elevated risk of death and may provide information complementary to the analysis of heart rate... - Efficacy and safety of vorapaxar in patients with prior ischemic strokeDavid A Morrow
Brigham and Women s Hospital, Boston, MA 02115, USA
Stroke 44:691-8. 2013..We tested the efficacy and safety of vorapaxar in a prespecified analysis in the stroke subcohort from a multinational, randomized, placebo-controlled trial... - Clopidogrel with or without omeprazole in coronary artery diseaseDeepak L Bhatt
Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
N Engl J Med 363:1909-17. 2010..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel... - Chronic angina: definition, prevalence, and implications for quality of lifeBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Rev Cardiovasc Med 10:S3-10. 2009..After a year of follow-up, though, much of the treatment differences are lost and all strategies (surgical/percutaneous revascularization or medical therapy) result in a significant improvement of angina symptoms... - Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2{degrees}P-TIMI 50Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115
Circulation 127:1522-9. 2013..Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization... - Established and novel biomarkers in ST-elevation myocardial infarctionJonathan W Waks
Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Future Cardiol 7:523-46. 2011.... - Prognostic evaluation of catalytic iron in patients with acute coronary syndromesDylan L Steen
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Clin Cardiol 36:139-45. 2013..Circulating catalytic iron ("free" iron) is that which is not bound to transferrin or ferritin and is available to generate reactive oxygen species that may have deleterious vascular effects... - Implementation of a Hospital-wide Protocol for Induced Hypothermia Following Successfully Resuscitated Cardiac ArrestPaul M Szumita
Department of Pharmacy, Brigham and Women s Hospital, Boston, MA, USA
Crit Pathw Cardiol 9:216-20. 2010..We describe our institutional guidelines for the initiation and management of induced hypothermia in patients successfully resuscitated from a cardiac arrest... - Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still outBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Circulation 113:2128-34; discussion 2151. 2006